US Food and Drug Administration Approval Summary: Capivasertib With Fulvestrant for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Locally Advanced or Metastatic Breast Cancer With
PIK3CA
/
AKT1
/
PTEN
Alterations
您需要登录后可以查看相关数据！